Background-Troponin elevation is a risk factor for mortality in patients with non-ST-segment-elevation acute coronary syndromes.
T roponin elevation in patients with acute coronary syndromes (ACS) indicates myocardial injury, typically secondary to atherosclerotic plaque rupture and thrombosis. A strong association between troponin elevation and adverse outcomes has been demonstrated in numerous studies [1] [2] [3] [4] ; however, 8% to 12% of patients presenting with non-ST-elevation ACS (NSTEACS) are found to have absent or only angiographically mild coronary lesions. [5] [6] [7] The pathophysiology of troponin elevation in these patients is not completely understood. 8, 9 Potential explanations include rupture of a mild plaque with endogenous thrombolysis before angiography; coronary artery spasm 10 ; mismatch between oxygen demand and supply, resulting in myonecrosis without plaque rupture as in type-2 myocardial infarction (MI) 11 ; and noncoronary causes of myocardial injury such as myocarditis. Regardless of the cause, the finding of nonocclusive coronary artery disease (CAD) in patients with NSTEACS and troponin elevation remains a diagnostic and therapeutic dilemma for the treating physician. 5, 12, 13 The prognosis of nonobstructive CAD in patients presenting with NSTEACS and troponin elevation has not been completely characterized to date, evaluated mainly in clinical registries without central event adjudication or core laboratory angiographic analysis, and typically limited by the small number of patients. 6, 7, 14, 15 We therefore sought to evaluate the impact of nonobstructive CAD in patients presenting with NSTEACS and troponin elevation enrolled from the largescale Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
Methods

Patient Population and Study Protocol
The ACUITY trial design has been previously described in detail. 16 In brief, moderate-and high-risk patients with NSTEACS were eligible for enrollment if they presented within 24 hours of symptoms typical of unstable or rest angina, with ≥1 of the following: (1) new ST-segment depression or transient elevation of ≥1 mm; (2) elevated troponin I, troponin T, or creatine kinase-muscle-brain levels; (3) known CAD; or (4) all 4 of the other variables of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina. Eligible patients were randomly assigned to treatment with 1 of 3 antithrombotic regimens starting immediately after randomization: heparin (unfractionated or enoxaparin, given at site discretion) plus glycoprotein IIb/IIIa inhibitor, bivalirudin plus glycoprotein IIb/IIIa inhibitor, or bivalirudin monotherapy. Angiography was performed per protocol within 72 hours after randomization, after which the decision was declared and recorded for principal treatment with percutaneous coronary intervention (PCI), coronary artery bypass graft surgery, or medical management. All patients undergoing PCI received dual antiplatelet therapy for a recommended duration of ≥1 year. The study was approved by the institutional review board or ethics committee at each participating center, and all patients signed written informed consent.
As part of a formal substudy, qualitative and quantitative coronary angiography was performed in 6921 consecutive patients at an independent core laboratory (Cardiovascular Research Foundation, New York, NY) by technicians blinded to randomization and clinical outcomes. Quantitative coronary angiography was performed in all lesions in the coronary tree with a visually estimated diameter stenosis (DS) of ≥30% and reference diameter ≥1.5 mm. An independent clinical events committee blinded to treatment assignment adjudicated all end point events.
The present analysis was restricted to patients from the angiographic substudy with abnormally elevated troponin I or troponin T levels at admission according to local laboratory upper limits of normal. These patients were further stratified by the presence or absence of obstructive CAD (based on prior studies, obstructive CAD was defined as quantitative DS >50% in any of the major coronary arteries, including all branches). 5, 14, 15 Patients with prior coronary artery bypass graft surgery were excluded.
Clinical End Points and Definitions
The primary end point definitions of the ACUITY trial have been previously detailed. 16 Clinical end points were assessed at 30 days and 1 year, consisting of composite ischemia (all-cause mortality, MI, or ischemiadriven revascularization), non-coronary artery bypass graft surgeryrelated major bleeding, and net adverse clinical events consisting of composite ischemia or major bleeding. The prespecified primary end points of interest for the current analysis were the 1-year rates of allcause mortality, subsequent MI, and unplanned revascularization.
Statistical Analysis
Clinical end points were assessed in relation to the presence or absence of obstructive CAD. Continuous variables were expressed as median and interquartile range and were compared using Wilcoxon rank-sum test. Categorical variables were compared with the χ 2 test or Fisher exact test. Kaplan-Meier methods were used to estimate event rates at follow-up and to plot time-to-event curves; comparisons were made using the log-rank test or the stratified log-rank test in the propensity score-matched cohort.
Because there were significant differences in baseline characteristics between patients with versus without obstructive CAD, we used propensity score matching to adjust for possible confounders. We performed a 3:1 matched analysis based on the propensity score of each patient. The log odds of the probability that a patient had nonobstructive CAD were modeled as a function of the identified confounders. Variables included in the model were age, sex, diabetes mellitus, insulin-treated diabetes mellitus, smoking, ST-segment deviation, history of MI, history of PCI, TIMI risk score, left ventricular ejection fraction, and creatinine clearance. Using the estimated logits, we first randomly selected a patient with nonobstructive CAD and then matched that patient with 3 patients in the obstructive CAD group with the closest estimated logit value. To assess the success of the matching procedure, we evaluated standardized differences of baseline covariates before and after matching. 17 Logistic regression was performed to identify independent predictors for nonobstructive CAD. The following covariates were included which in prior studies have been demonstrated to be prognostically important in patients with ACS: age, sex, diabetes mellitus, hypertension, current smoking, hyperlipidemia, history of MI, renal insufficiency, ST-segment deviation ≥1 mm, and troponin level. The number of variables was limited to 1 per ≥15 events to avoid model overfitting. Analyses were 2-sided, and significance was established at the 0.05 level. Statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC).
Results
Patients and Procedures
Among the 6921 patients in the formal angiographic substudy of the ACUITY trial, 2422 patients had elevated troponin T or troponin I levels. Of these, 2245 patients (91.9%) had obstructive lesions (quantitative coronary angiography DS >50%) and 197 patients (8.1%) had no obstructive lesions on coronary angiography. Baseline clinical characteristics of patients with elevated troponin levels stratified by the presence or absence of obstructive CAD in the entire cohort and
WHAT IS KNOWN
• Troponin elevation is associated with increased mortality in patients with acute coronary syndrome.
• Data about the predictors, characteristics and prognosis of patients admitted with non-ST-elevation acute coronary syndrome, troponin elevation, and nonobstructive coronary artery disease are lacking.
WHAT THE STUDY ADDS
• Nearly 9% of patients admitted with acute coronary syndrome symptoms and troponin elevation have nonobstructive coronary artery disease on admission angiogram.
• Compared with acute coronary syndrome patients with obstructive coronary artery disease, patients with nonobstructive coronary artery disease have a higher adjusted risk of mortality mainly from noncardiac causes but lower rates of subsequent myocardial infarction and unplanned revascularization.
propensity-matched groups are presented in Table 1 . In the entire cohort, patients with obstructive CAD were older, more frequently male, with more classic cardiovascular risk factors, including a higher prevalence of diabetes mellitus, hyperlipidemia, and prior MI and PCI, and more frequently presented with ST-segment deviation ≥1 mm.
The propensity score adjustment yielded 117 patients with nonobstructive CAD (59.4% of all patients with nonobstructive CAD) matched with 331 patients with obstructive CAD. Baseline characteristics were similar between the matched groups ( Table 1 ).
There were no significant differences in medical therapy at hospital admission in patients with versus without obstructive CAD except for a higher rate of aspirin use in patients with obstructive CAD (Table 2) . However, patients with nonobstructive CAD were less likely to be treated with a thienopyridine, statins, and β-blockers at discharge, 1-month, and 1-year follow-up. These differences remained significant in the matched cohort. Of 1649 patients who were on glycoprotein IIb/III inhibitors (either with heparin or with bivalirudin), 9.8% had nonobstructive CAD, whereas of 830 patients not on glycoprotein IIb/III inhibitors therapy, 8.6% had nonobstructive CAD (P=0.38).
Not surprisingly, angiographic findings as assessed by the core laboratory (Table 3 ) demonstrated a greater DS in all 3 major coronary arteries, higher rates of TIMI 0/1 flow, lower blush score, and more high-risk lesion characteristics (ulceration, thrombus, calcification, and ectasia) in patients with obstructive CAD. These differences remained highly significant in the matched cohort. Consequently, in the entire cohort, revascularization (PCI or coronary artery bypass graft surgery) was performed in 87.5% of patients with obstructive CAD versus 2.5% of the patients with nonobstructive CAD (the latter either because of operator overestimation of lesion severity or the presence of a visible thrombus or ruptured plaque characteristics warranting revascularization), a difference that also remained highly significant in the matched cohort.
There were no differences in baseline left ventricular ejection fraction, segmental wall motion abnormalities, and mitral regurgitation between the 2 groups either before or after matching. Nevertheless, based on left ventriculography, 16 of our patients (8.1% of those with nonobstructive CAD) had findings compatible with apical ballooning (Tako-Tsubo syndrome). There were no patients with apical ballooning in the obstructive CAD group. Data are expressed as % (n) or median (interquartile range). CAD indicates coronary artery disease; CRP, C-reactive protein; GPI, glycoprotein IIb/IIIa inhibitor; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; and WBC, white blood cell count.
All patients included in the current analysis had abnormally elevated troponin I or troponin T levels. Creatine kinase-muscle-brain levels were higher in patients with obstructive CAD; there was a trend toward higher troponin levels in patients with obstructive CAD (Table 4 ).
Nonobstructive CAD and Outcome
In the entire cohort, despite significantly lower TIMI risk score and fewer cardiovascular risk factors, cardiac and allcause mortality were similar in patients with and without obstructive CAD. However, 30-day and 1-year noncardiac mortality tended to be higher in patients with nonobstructive CAD (Table 5 ). Conversely, patients with obstructive CAD were at significantly higher risk for recurrent MI and unplanned revascularization. There were no differences in the rates of major bleeding, stent thrombosis, or cerebrovascular events.
Among the propensity score-matched patients, all-cause mortality was higher in patients with nonobstructive CAD, driven by greater noncardiac mortality (Table 6 ; Figure  [ Because troponin elevations may occur in patients with renal insufficiency without ACS, we repeated the analysis after exclusion of patients with renal insufficiency. The impact of nonobstructive CAD on clinical outcomes did not change both in the entire cohort ( Table I in the Data Supplement) and the propensity-matched cohort ( Table II in the Data Supplement).
Sensitivity analysis was performed using 30% DS and 70% DS as cutoffs to define obstructive versus nonobstructive CAD. With the 30% DS cutoff, unadjusted mortality rates were similar between the groups, with higher noncardiac mortality at 30 days, consistent with the main results. With 70% DS as the cutoff, unadjusted mortality rates were similar between the groups, with lower cardiac mortality rates at 30 days and 1 year in patients with nonobstructive CAD, with a trend toward higher noncardiac mortality (Tables III and IV 
Predictors of Nonobstructive CAD
By multivariable analysis, independent predictors of nonobstructive CAD among patients admitted with NSTEACS and troponin elevation were renal insufficiency and female sex. Older age, the presence of diabetes mellitus, smoking, previous MI, and baseline ST-segment deviation ≥1 mm were predictors for obstructive CAD. Of note, troponin level was not a predictor of obstructive CAD (Table 7 ).
Discussion
From the large-scale ACUITY trial of moderate-and highrisk patients with NSTEACS, nonobstructive CAD was found Data are expressed as % (n). ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; and CAD, coronary artery disease. in 8.1% of patients with baseline troponin elevation. Patients with nonobstructive CAD were at higher risk for all-cause mortality compared with propensity score-matched patients with obstructive CAD, driven by greater noncardiac mortality. Conversely, the rates of recurrent MI and revascularization were lower in patients with nonobstructive compared with obstructive CAD. Independent predictors for nonobstructive CAD among troponin-positive patients presenting with NSTEACS symptoms were female sex, younger age, renal insufficiency, and the absence of diabetes mellitus, prior MI, and baseline ST-segment deviation. The present analysis is by far the largest study to date to evaluate the characteristics and prognosis of patients admitted with ischemic symptoms, troponin elevation, and nonobstructive CAD as quantitatively evaluated by a central angiographic core laboratory. Furthermore, no prior study has compared troponin-positive NSTEACS patients without obstructive CAD to a matched group of patients with obstructive CAD. With these limitations in perspective, prior studies had reported conflicting results regarding the outcomes of patients with ACS and nonobstructive CAD. A pooled analysis from the TIMI 11B, TIMI 16, and TIMI 22 trials reported a 1% mortality rate and a 12.1% rate of composite death, MI, or unstable angina through 1 year in patients with nonobstructive CAD; however, only 60% of the patients had elevated cardiac biomarkers, and no comparison was performed with patients with obstructive CAD. 5 Data are expressed as % (n) or median (interquartile range). CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; %DS, percent diameter stenosis; PCI, percutaneous coronary intervention; and TIMI, thrombolysis in myocardial infarction.
A retrospective analysis of non-STsegment-elevation MI patients from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) database demonstrated lower in-hospital mortality in patients with nonobstructive CAD compared
with those with obstructive CAD. However, in this study, angiographic findings and clinical events were site recorded and not centrally adjudicated. Long-term outcomes were not reported. 6 nonobstructive CAD, and thus, no direct comparison was possible between patients with troponin elevation and obstructive versus nonobstructive CAD. 14 The increased mortality observed in patients with nonobstructive compared with obstructive CAD in the present study is surprising and not completely understood. Coronary angiography underestimates plaque burden and the presence of plaque rupture. Consequently, a disrupted plaque may be histologically present despite a mild angiographic stenosis. 18 Plaque erosion without rupture has been also suggested as a cause for ACS in patients with nonobstructive CAD. 19 Moreover, early initiation of antithrombotic and antiplatelet therapy in ACS may lyse thrombus, leaving behind an angiographically insignificant lesion which may be inherently unstable. Patients with nonobstructive lesions may thus be mistakenly classified as low risk and may not receive adequate secondary prevention measures. Indeed, in this study, patients with nonobstructive CAD were less likely to be treated with dual antiplatelet therapy, statins, and β-blockers. Coronary artery vasospasm may also cause angina and troponin elevation in the absence of obstructive CAD. Although coronary vasospasm is usually benign, it may be associated with MI and sudden cardiac death. 10, 20 Unfortunately, we do not have data regarding coronary vasospasm provocation tests in the current study. Additionally, an important alternative diagnosis in patients presenting with symptoms suggestive of ACS, troponin elevation, and nonobstructive CAD is apical ballooning or stress-induced cardiomyopathy. 21 In the current cohort, patients with apical ballooning had an excellent prognosis with 0% mortality. As shown in prior study of unselected hospitalized patients with troponin elevation, nonthrombotic causes were associated with a worse prognosis than classic ACS. 12 Troponin elevation in these patients may divert attention from an underlying primary noncardiac condition. 22 In the current propensity-matched cohort, the leading causes of death in patients with nonobstructive CAD were noncardiac. Whether standard ACS therapy is ineffective or even harmful in these patients is unknown. Our results may have important clinical implications. Given the high mortality observed in patients presenting with ACS symptoms, troponin elevation, and nonobstructive CAD, the cause should be thoroughly sought and patients should be followed closely especially during the first few months. Coronary spasm provocation tests should be considered during the initial angiogram. 10, 19 Imaging modalities such as intravascular ultrasound, optical coherence tomography, CT angiography, 23 and MRI should also be considered to differentiate between plaque rupture, plaque erosion, type-2 MI, myocarditis, cardiomyopathy, and Tako-Tsubo syndrome. Further studies are needed to confirm our findings and guide clinical practice.
Limitations
First, this study, although prespecified, is based on a retrospective analysis from a prospective study and should thus be considered hypothesis generating. As the most sophistical propensity adjusted multivariable analysis cannot exclude the effect of unmeasured confounders, the associations we have identified do not imply causality. Second, an empirical cutoff of DS <50% on quantitative coronary angiography was used to define nonobstructive CAD. This cutoff does not necessarily differentiate between thrombotic and nonthrombotic pathologies (although fewer angiographic complex plaques were present in the nonobstructive group). The results were not substantially changed when 30% and 70% DS cutoffs were used to define nonobstructive CAD. Third, intravascular imaging and coronary artery vasospasm provocation tests were not routinely performed in ACUITY, which could have better differentiated between atherothrombotic and nonatherothrombotic causes. Fourth, despite the large size of the ACUITY trial, the absolute number of patients with troponin elevation and nonobstructive CAD in the present report is still modest. Finally, given the specific inclusion and exclusion criteria of the ACUITY trial, these results may not be applicable for patients with different characteristics and for those presenting with noncardiac presentations in whom troponin elevations are incidentally noted. 24 
Conclusions
In the large-scale ACUITY trial, patients presenting with symptoms of NSTEACS and elevated troponin levels in whom obstructive CAD was absent were at significantly higher risk of 1-year all-cause mortality than those with obstructive CAD, despite lower rates of unplanned revascularization and subsequent MI. The poor prognosis of these patients must be recognized so that a near normal angiogram does not drive diagnostic and therapeutic complacency. Most importantly, given the poor prognosis of these patients, the search for the cause of the troponin elevation should be comprehensive, with additional imaging and testing considered to exclude coronary artery spasm or angiographically nonevident ruptured plaques and coronary thrombosis. In the absence of any indication of an epicardial coronary cause of troponin elevation in the patient with NSTEACS symptoms, further work-up is required to identify other potential cardiac or noncardiac causes to direct appropriate short-term and long-term therapy.
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